Argenx
ARGX
#455
Rank
S$70.68 B
Marketcap
S$1,130
Share price
3.37%
Change (1 day)
55.85%
Change (1 year)
Argenx is a Dutch company that develops antibody therapies to fight autoimmune diseases and cancer.

Earnings for Argenx (ARGX)

Earnings in 2026 (TTM): S$1.92 Billion

According to Argenx 's latest financial reports the company's current earnings are S$4.66 Billion. In 2025 the company made an earning of S$1.65 Billion, an increase over its 2024 earnings that were of S$0.11 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Argenx from 2013 to 2026

Annual earnings

Year Earnings Change
2026 (TTM) S$1.92 B16.75%
2025 S$1.65 B1400.64%
2024 S$0.11 B-127.97%
2023 -S$0.4 Billion-58.25%
2022 -S$0.95 Billion80.17%
2021 -S$0.53 Billion
2019 -S$0.26 Billion124.86%
2018 -S$0.12 Billion131.81%
2017 -S$49.28 Million
2015 -S$23.79 Million
2013 -S$14.39 Million